Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Redefining Left Ventricular Assist Device Indications and Strategies

Redefining Left Ventricular Assist Device Indications and Strategies Letters Author Affiliations: Division of Cardiothoracic Anesthesiology, Department of COMMENT & RESPONSE Anesthesiology, Virginia Commonwealth University, Richmond (Pal, Nelson); Department of Anesthesiology, Virginia Commonwealth University, Richmond Redefining Left Ventricular Assist Device Indications (Butterworth). and Strategies Corresponding Author: Nirvik Pal, MD, Division of Cardiothoracic To the Editor We read the study by Goldstein et al with Anesthesiology, Department of Anesthesiology, Virginia Commonwealth great interest. Based on secondary analysis of the Multi- University, 1250 E Marshall St, PO Box 980541, 5th Floor, Richmond, VA 23298 (nirvik.pal@vcuhealth.org). center Study of MagLev Technology in Patients Undergoing Published Online: September 23, 2020. doi:10.1001/jamacardio.2020.4303 Mechanical Circulatory Support Therapy With HeartMate 3 Conflict of Interest Disclosures: None reported. (MOMENTUM) 3 trial showing superior outcomes with 1. Goldstein DJ, Naka Y, Horstmanshof D, et al. Association of clinical outcomes HeartMate 3 pumps, the authors challenge the utility of with left ventricular assist device use by bridge to transplant or destination more than 2-decades-old predefined indications for left ven- therapy intent: the Multicenter Study of MagLev Technology in Patients tricular assist device (LVAD) therapy, namely, bridge to Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 transplant, bridge to candidacy, and destination therapy. (MOMENTUM 3) randomized clinical trial. JAMA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Redefining Left Ventricular Assist Device Indications and Strategies

JAMA Cardiology , Volume 6 (1) – Jan 23, 2021

Loading next page...
 
/lp/american-medical-association/redefining-left-ventricular-assist-device-indications-and-strategies-8Z48KA3DTY
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.4320
Publisher site
See Article on Publisher Site

Abstract

Letters Author Affiliations: Division of Cardiothoracic Anesthesiology, Department of COMMENT & RESPONSE Anesthesiology, Virginia Commonwealth University, Richmond (Pal, Nelson); Department of Anesthesiology, Virginia Commonwealth University, Richmond Redefining Left Ventricular Assist Device Indications (Butterworth). and Strategies Corresponding Author: Nirvik Pal, MD, Division of Cardiothoracic To the Editor We read the study by Goldstein et al with Anesthesiology, Department of Anesthesiology, Virginia Commonwealth great interest. Based on secondary analysis of the Multi- University, 1250 E Marshall St, PO Box 980541, 5th Floor, Richmond, VA 23298 (nirvik.pal@vcuhealth.org). center Study of MagLev Technology in Patients Undergoing Published Online: September 23, 2020. doi:10.1001/jamacardio.2020.4303 Mechanical Circulatory Support Therapy With HeartMate 3 Conflict of Interest Disclosures: None reported. (MOMENTUM) 3 trial showing superior outcomes with 1. Goldstein DJ, Naka Y, Horstmanshof D, et al. Association of clinical outcomes HeartMate 3 pumps, the authors challenge the utility of with left ventricular assist device use by bridge to transplant or destination more than 2-decades-old predefined indications for left ven- therapy intent: the Multicenter Study of MagLev Technology in Patients tricular assist device (LVAD) therapy, namely, bridge to Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 transplant, bridge to candidacy, and destination therapy. (MOMENTUM 3) randomized clinical trial. JAMA

Journal

JAMA CardiologyAmerican Medical Association

Published: Jan 23, 2021

References